Rho GDP protein expression change and investigation of itseffect on GDP/GTP cycle in human brain oligodendroglioma

Iranian Journal of Cancer Prevention

Volumn 6, Issue SUPPL.1, 2013, Pages 24-29

  Abad, Solmaz Khaghani Razi ^a,b   Pooladi, Mehdi ^a,b   Hashemi, Mehrdad ^b   Moradi, Afshin ^c,d   Sobhi, Sara ^d   Zali, Alireza ^c   Mousavi, Masoumea ^a   Zali, Hakimeh ^a   Azodi, Mona Zamanian ^a   Rakhshan, Azadeh ^c   Vafaee, Reza ^a   Rezaei Tavirani, Mostafa ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brain tumors; Oligodendroglioma; Proteomics; Rho GDP; Two dimensional electrophoresis

Indexed keywords

RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; ISOELECTRIC FOCUSING; MOLECULAR DIAGNOSIS; OLIGODENDROGLIOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 84875319968     PISSN: 20082401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gollapalli K, Ray S, Srivastava R, Renu D, Singh P, Dhali S,et al. Investigation of serum proteome alterations in human Glioblastoma Multiforme. PMIC. 2012; 23: 1-18.
2. Riemenschneider ML, Jeuken JWM, Wesselling P, Reifenberger G. Molecular diagnostics of Glioma: stste of the art. Acta Neuropathol. 2010; 120: 567-584.
3. Sanai N, Buylla AA, Berger M. Neural stem cells and the origin of Gliomas. New England Journal of Medicine. 2005; 353: 811-822.
4. Kirdar L, Tsuslu H, Bozbuga M. Primary brain tumors associated with cerebral aneurysm: report of three cases. Turkish Neurosurgery. 2009; 21: 216-221.
5. Gajadhar A, De Souza LV, Siu KWM, Guha A. Primary malignant brain tumours - current and potential impact of proteomics-based analysis. Touch Briefings. 2010; 73-76.
6. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M et al. Molecular classification and survival prediction in human Glioma based onproteom analysis. Cancer Research. 2004; 64: 2496-2501.
7. Heuvel H, Den V, Heck AJR. Native Protein mass spectrometry: from intact Oligomers to functional machineries. Current Opinion in Chemical Biology. 2004; 8: 519-526.
8. Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of Glioma: methods and application. Expert Review of Molecular Diagnostics. 2009; 9: 695-707.
9. Chen X, Zang W, Xue F, Shen Z, Zhang Q. Bioinformatics Analysis Reveals Potential Candidate Drugs For Different Subtypes Of Glioma. Neurol Sci. 2012; 12: 1-3.
10. Boja ES, Rodriguez H. The path to clinical proteomics reesearch: integration of Proteomics, Genomics, cllinical laboratory and regulatory science. Korean J Lab Med. 2011; 1: 61-71.
11. Thirant C, Varlet P, Lipecka J, Gall ML, Broussard C, Chafey P, et al. Proteomics analaysis of Oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. Proteomics- journal. 2011; 11: 4139-4154.
12. Matharoo-Ball B, Miles AK, Creaser CS, Ball G, Rees R. Serum biomarker profiling in cancer studies: a question of standardization? Nottingham Trent University Journal Compilation. 2008; 6: 224-247.
13. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Molecular Cancer. 2007; 6: 1-13.
14. Weiss W, Gorg A. High-Resolution Two- Dimensional Electrophoresis. Proteomics methods in molecular biology. 2009; 564: 13-20.
15. Deighton RF, Short DM, RJ Mc, Gregor AJG, Wittle IR, Mc Culloch J. The utility of functional interaction and cluster analysis in CNS Proteomics. Journal of Neuroscience Methods. 2009; 180:321-329.
16. Sabarni KC, Zettr B. Cancer biomarkers: knowing the present and predicting the future. Future Medicine, Oncology. 2005;1: 37-50.
17. Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, et al. Proteomic-Based prognosis of brain tumor patients using direct-tissue matrix- assisted laser desorption ionization mass spectrometry. Cancer Res. 2005; 65: 7674-7681.
18. Graner MW, Alzate O, Deckkovskaia AM, Keene JD, Sampson JH, Mitchell DA,et al. Proteomic and immunologic analysis of brain tumor exosomes. The FASEB Journal Research Communication. 2009; 23: 1541-1557.
19. Masui K, Cloughesy TF, Mischel PC. Review: Molecular pathology in adult high-grade Gliomas: form molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology. 2012; 38: 271-291.
20. Carlesson A, Person O, Ingvarsson J, Widegren B, Salford L, Borrebaeck CAK, et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in Glioblastoma Multiforme patients. Proteomics Clinical. 2010; 4: 591-602.
21. Signorelli F, Guyotat J, Elisevich K, Barbagallo MV. Review of current microsurgical of insular Glioma. Acta Neurochir. 2009; 10: 1-5.
22. Park CK, Kim JH, Moon M J, Jung J H, Lim SY, Park S H, et al. Investigation of molecular factors associated with malignant transformation of Oligodendroglioma by Proteomic study of a single case of rapid tumor progression. Journal Cancer Re Clin Oncol. 2008; 34: 255-262.
23. Zhuang Z, Qi M, Li J, Okamoto H, Xu DS, Iyer RR. Proteomic identification of glutamine synthetase as a differential marker for Oligodendrogliomas and astrocytomas. J Neurosurg. 2011; 115 (4): 789-795.
24. Chiang W-F, Ho H-C, Chang H-Y, Chiu C-C, Chen Y-L, Hour T-C, et al. Overexpression of Rho GDP-dissociation inhibitor alpha predicts poor survival in oral squamous cell carcinoma. Oral Oncology. 2011; 47: 452-458.
25. Sze Law JW, Lee AYW. The Role of Semaphorins and Their Receptors in Gliomas. Journal of Signal Transduction. 2012; 10: 1-14.
26. Tu Y, Lu J, Fu J, Cao Y, Fu G, Kang R, et al. Over-expression of Neuroepithelial-transforming Protein 1 Confers Poor Prognosis of Patients with Gliomas. Jpn J Clin Oncol. 2010; 40: 388-394.